Mishima, H., Oba, K., Sakamoto, J., Muro, K., Yoshino, T., Hyodo, I., & Maehara, Y. (2012). FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study). Oxford University Press.

Mishima, Hideyuki, Koji Oba, Junichi Sakamoto, Kei Muro, Takayuki Yoshino, Ichinosuke Hyodo, i Yoshihiko Maehara. FOLFIRI Plus Bevacizumab 5 Mg/kg Versus 10 Mg/kg As Second-line Therapy in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study). Oxford University Press, 2012.

Mishima, Hideyuki, et al. FOLFIRI Plus Bevacizumab 5 Mg/kg Versus 10 Mg/kg As Second-line Therapy in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study). Oxford University Press, 2012.